Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease
- Sponsor
- Assiut University
- Study ID
- NCT07200869
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Sickle Cell Disease
- Vaso-occlusive Crisis
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- No intervention — OTHERretrospective observational study. No intervention will be administered; data will be collected from existing medical records of pediatric sickle cell patients at Assiut University Hospital.
Study Details
This study aims to assess the incidence and clinical outcomes of vaso-occlusive crises in pediatric patients with sickle cell disease. Data will be collected and analyzed to identify risk factors and related complications.
Key Dates
- First listed
- Oct 1, 2025
- Start date
- Oct 31, 2025
- Status verified
- Sep 2025
- Primary completion
- Oct 31, 2027
- Completion
- Nov 30, 2027
Study Design
- Enrollment
- 25 participants (estimated)
Arms
- Arm: Sickle Cell pediatric patientsChildren with sickle cell disease whose medical records will be retrospectively reviewed at Assiut University Hospital.
Primary Outcome Measure
Incidence of vaso-occlusive crisis in pediatric sickle cell patients [ Time Frame: Retrospective review of medical records from 2019 to 2024 ]
Central Contacts
- Nadia Fawzy, Pediatrician+201552865958
- Assiut University research office
Find similar trials
Nationwide
Related Studies
- Blood Collection for Research Related to Certain Diseases Involving Blood VesselsEnrolling By Invitation · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Blood Sampling for Research Related to Sickle Cell DiseaseRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseasePHASE1 · Recruiting · Abdullah Kutlar · Augusta, Georgia
- Sickle Cell Clinical Research and Intervention ProgramRecruiting · St. Jude Children's Research Hospital · Peoria, Illinois